The St. Jude valve prosthesis: analysis of the clinical results in 815 implants and the need for systemic anticoagulation

Cora and Webb Mading Department of Surgery, Baylor College of Medicine, Houston, Texas 77030.

Between July 1979 and December 1984, 785 patients received 815 St. Jude Medical valve prostheses. Valve-related mortality in the follow-up period was due to thromboembolism in seven cases, anticoagulant-related hemorrhage in three and perivalvular leak in two. Freedom from valve-related death or reoperation at 3 years was 96.4% for aortic valve replacement and 98.3% for mitral valve replacement. The overall rate of thromboembolism was 2.6%/patient-year with warfarin, 9.2%/patient-year with antiplatelet medication and 15.6%/patient-year in patients with no anticoagulant therapy. One episode of thrombotic obstruction of a mitral valve, in a patient receiving no anticoagulant therapy, resulted in an occurrence rate of such obstruction of 0.22%/patient-year. Valve replacement with the St. Jude valve produced excellent clinical results, but long-term anticoagulation with warfarin was required to minimize thromboembolic complications. The use of antiplatelet agents alone provided inadequate protection.

This article has been cited by other articles:

				S. Torregrosa, J. Gomez-Plana, F. J. Valera, J. Caffarena, J. M. Maronas, F. Garcia-Sanchez, J. Peris, R. Frias, and J. M. Caffarena Long-term clinical experience with the omnicarbon prosthetic valve Ann. Thorac. Surg., September 1, 1999; 68(3): 881 - 886. [Abstract] [Full Text] [PDF]

				J. W. Tam, R. G. Masters, I. G. Burwash, A. D. Mayhew, and K.-L. Chan Management of Patients With Mild Aortic Stenosis Undergoing Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 1998; 65(5): 1215 - 1219. [Abstract] [Full Text] [PDF]

				L-F. Debetaz, P. Ruchat, M. Hurni, A. Fischer, F. Stumpe, H. Sadeghi, G. van Melle, and J-J. Goy ST. JUDE MEDICAL VALVE PROSTHESIS: AN ANALYSIS OF LONG-TERM OUTCOME AND PROGNOSTIC FACTORS J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 134 - 148. [Abstract] [Full Text]

				A. K. Cabalka, R. W. Emery, R. J. Petersen, H. K. Helseth, M. Jakkula, K. V. Arom, and D. M. Nicoloff Long-term follow-up of the St. Jude medical prosthesis in pediatric patients Ann. Thorac. Surg., December 1, 1995; 60(suppl_3): S618 - S623. [Abstract] [PDF]

				R. P. Cochran, K. S. Kunzelman, A. C. Eddy, B. O. Hofer, and E. D. Verrier Modified conduit preparation creates a pseudosinus in an aortic valve-sparing procedure for aneurysm of the ascending aorta J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1049 - 1058. [Abstract] [Full Text]

				M. Sturzenegger, J. H. Beer, and F. Rihs Monitoring Combined Antithrombotic Treatments in Patients With Prosthetic Heart Valves Using Transcranial Doppler and Coagulation Markers Stroke, January 1, 1995; 26(1): 63 - 69. [Abstract] [Full Text]

				S. Khan, A. Chaux, J. Matloff, C. Blanche, M. DeRobertis, R. Kass, T. P. Tsai, A. Trento, S. Nessim, R. Gray, et al. The St. Jude Medical valveExperience with 1000 cases J. Thorac. Cardiovasc. Surg., December 1, 1994; 108(6): 1010 - 1020. [Abstract] [Full Text]

				M. Ibrahim, H. O'Kane, J. Cleland, D. Gladstone, M. Sarsam, and C. Patterson The St. Jude Medical prosthesisA thirteen-year experience J. Thorac. Cardiovasc. Surg., August 1, 1994; 108(2): 221 - 230. [Abstract] [Full Text]

				J. Fernandez, G. W. Laub, M. S. Adkins, W. A. Anderson, C. Chen, B. M. Bailey, L. M. Nealon, and L. B. McGrath Early and late-phase events after valve replacement with the St. Jude Medical prosthesis in 1200 patients J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 394 - 407. [Abstract] [Full Text]

				V. J. DiSesa, J. J. Collins Jr, and L. H. Cohn Hematological complications with the St. Jude valve and reduced-dose Coumadin Ann. Thorac. Surg., August 1, 1989; 48(2): 280 - 283. [Abstract] [PDF]

				ANTICOAGULATION NECESSARY WITH ST. JUDE VALVE PROSTHESIS Journal Watch (General), January 24, 1989; 1989(124): 1 - 1. [Full Text]